

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF CR SANJIU FOR THE YEAR ENDED 31 DECEMBER 2023

On 24 January 2024, CR Sanjiu released its results estimate for the year ended 31 December 2023.

China Resources Sanjiu Medical & Pharmaceutical Company Limited (華潤三九醫藥股份有限公司) (“**CR Sanjiu**”) is a company incorporated in the People’s Republic of China. The shares of CR Sanjiu are listed on the Shenzhen Stock Exchange. As of the date of this announcement, CR Sanjiu is indirectly owned as to 63.00% by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and is a subsidiary of the Company.

On 24 January 2024, CR Sanjiu released its results estimate for the year ended 31 December 2023, in which, it announced that the net profit attributable to the shareholders of CR Sanjiu for the year ended 31 December 2023 is estimated to range from approximately RMB2,818 million to RMB3,065 million (as compared to the same period last year of net profit of approximately RMB2,448.8021 million), net profit attributable to the shareholders of CR Sanjiu excluding non-recurring gain or loss is estimated to range from approximately RMB2,678 million to RMB2,888 million (as compared to the same period last year of net profit of approximately RMB2,218.9172 million), basic earnings per share is estimated to range from approximately RMB2.87 per share to approximately RMB3.12 per share (as compared to the same period last year of profit per share of approximately RMB2.48 per share) (the “**CR Sanjiu Results Estimate**”).

The reasons for the change in results are that, during the year ended 31 December 2023, CR Sanjiu has responded actively to market changes and followed industry development trends, continuously pursued innovation and upgrades, strengthened brand building, and optimized product structure. Furthermore, KPC Pharmaceuticals, Inc (昆藥集團股份有限公司) has been included in the consolidated financial statements of CR Sanjiu since 19 January 2023, contributing to the improvement of profitability.

The CR Sanjiu Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For details of the financial data, those to be disclosed in the annual report for the year ended 31 December 2023 to be issued by CR Sanjiu shall prevail.

The financial information in this announcement is limited to CR Sanjiu only and does not represent or provide a complete view of the operational of financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 25 January 2024

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.